Skip to main content

Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls

Journal of Neuro-Oncology volume 107, pages 373–378 (2012)Cite this article

Abstract

Convection-enhanced delivery (CED) of compounds into brain tumors reportedly circumvents the blood brain barrier. CED intends to increase drug delivery to malignant cells, reaching high local therapeutic concentration and decreasing or eliminating systemic side effects. Clinical experience and published data on catheter placement (CP) surgery are scarce. We propose practical and technical guidelines for planning CED based on our experience. We retrospectively analyzed the medical charts and relevant neuroimages of 25 patients following the insertion of 64 CED catheters. The patients were enrolled in at least one of four clinical trials using CED for treating recurrent glioblastoma multiforme in our institution between 2003–2006. Intra- and postoperative complications related to CP surgery and the difficulties and pitfalls of planning were evaluated. There were 29 CP surgeries. Forty-four peritumoral brain tissue catheters were inserted in 16 CP surgeries following tumor resection in 16 patients, and 20 catheters were placed into the tumor in 13 procedures in 10 patients. The lesions were in or near eloquent brain tissue areas in 13 of all CP surgeries. Complications included increased edema (31%), infection (6.9%), bleeding (6.9%) and seizures (13.8%). Significant neurological deterioration occurred in 4 patients (13.8%). Difficulties in adhering to CP surgery guidelines included lesion site (superficial, mesial temporal lobe, proximity to CSF spaces), proximity to eloquent cortical areas, tissue density that interfered with the trajectory, and technical limitations of stereotactic instruments. CED procedures for high-grade gliomas may be associated with surgical morbidity. Adherence to guidelines might be difficult because of lesion site and complicated by brain and tumor tissue characteristics. This should be considered while planning clinical trials that use convection-based technology.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198

    PubMed  Article  CAS  Google Scholar 

  2. Chamberlain MC (2006) Treatment options for glioblastoma. Neurosurg Focus 20:E2

    Article  Google Scholar 

  3. Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW et al (1991) Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74:441–446

    PubMed  Article  CAS  Google Scholar 

  4. Bouvier G, Penn RD, Kroin JS, Beique R, Guerard MJ (1987) Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 20:286–291

    PubMed  Article  CAS  Google Scholar 

  5. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076–2080

    PubMed  Article  CAS  Google Scholar 

  6. Ferguson S, Lesniak MS (2007) Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 4:169–180

    PubMed  Article  CAS  Google Scholar 

  7. Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart-Henney PA, Koong SS, Cummins A, Paik CH, Oldfield EH (1997) Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 87:586–594

    PubMed  Article  CAS  Google Scholar 

  8. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH (1999) Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90:315–320

    PubMed  Article  CAS  Google Scholar 

  9. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:1021–1029

    PubMed  Article  CAS  Google Scholar 

  10. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL (1994) High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266:R292–R305

    PubMed  CAS  Google Scholar 

  11. Debinski W (2002) Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest 20:801–809

    PubMed  Article  CAS  Google Scholar 

  12. Kawakami M, Kawakami K, Puri RK (2003) Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 65:15–25

    PubMed  Article  Google Scholar 

  13. Kioi M, Kawakami K, Puri RK (2004) Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 10:6231–6238

    PubMed  Article  CAS  Google Scholar 

  14. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25:837–844

    PubMed  Article  CAS  Google Scholar 

  15. Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362–1368

    PubMed  Article  CAS  Google Scholar 

  16. Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65:3–13

    PubMed  Article  Google Scholar 

  17. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472–479

    PubMed  Article  CAS  Google Scholar 

  18. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, Faibel M, Nass D, Hadani M, Orenstein A, Cohen JS, Ram Z (2001) Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61:4971–4973

    PubMed  CAS  Google Scholar 

  19. Verwijnen SM, Sillevis Smith PA, Hoeben RC, Rabelink MJ, Wiebe L, Curiel DT, Hemminki A, Krenning EP, de Jong M (2004) Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene. Cancer Biother Radiopharm 19:111–120

    PubMed  Article  CAS  Google Scholar 

  20. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, Carpenter SP, Shan JS (2005) Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56:1243–1252; discussion 1252–1243

    Google Scholar 

  21. Sampson JH, Archer G, Pedain C, Wembacher-Schroder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodriguez-Ponce MI, Chang SM, Mittermeyer S, Croteau D, Puri RK (2010) Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113:301–309

    PubMed  Article  Google Scholar 

  22. Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C (2007) Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 60:ONS89-98; discussion ONS98-89

    Google Scholar 

  23. Degen JW, Walbridge S, Vortmeyer AO, Oldfield EH, Lonser RR (2003) Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 99:893–898

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurosurgery, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6 Weizman Street, 64239, Tel Aviv, Israel

    Tal Shahar & Zvi Ram

  2. Stereotactic Radiosurgery Service, Department of Neurosurgery, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 6 Weizman Street, 64239, Tel Aviv, Israel

    Andrew A. Kanner

Authors
  1. Tal Shahar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zvi Ram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew A. Kanner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew A. Kanner.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shahar, T., Ram, Z. & Kanner, A.A. Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls. J Neurooncol 107, 373–378 (2012). https://doi.org/10.1007/s11060-011-0751-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-011-0751-x

Keywords

  • Stereotactic
  • Catheter placement
  • Convection-enhanced delivery
  • Glioma
  • Surgery